Phase III ECZTRA 6 and ECZTEND trials of Adbry in atopic dermatitis reported at AAD 2023 Annual Meeting.- LEO Pharma
S. aureus is consistently found in the skin lesions of patients with AD and contributes to skin irritation and infections. A correlation between disease severity and S. aureus colonization has been demonstrated in clinical studies. At Week 16, 49% of patients receiving Adbry 150 mg (n=81) and 43% of patients receiving Adbry 300 mg (n=82) went from testing positive for S. aureus to negative in lesional skin, compared to the 14% receiving placebo (n=80). Similar reductions were seen in Adbry-treated patients with S. aureus positive non-lesional skin.
Additional data in adolescent patients from ECZTRA 6 demonstrated that 16 weeks of treatment with Adbry showed an improvement in skin gene expression from a lesional to a non-lesional skin profile. The improvement occurred in 29% (n=29) and 41% (n=27) of the differentially expressed genes in lesional skin in patients treated with Adbry (for the 150 mg and 300 mg groups, respectively), compared to a 4% improvement in the placebo group (n=27). At Week 8, Adbry 150 mg and 300 mg led to 35% 9 (n=29) and 33% (n=27) improvement respectively in gene expression, compared to a 10% (n=27) improvement with placebo.
All participants who completed the ECZTRA 6 trial were eligible to enter the ongoing ECZTEND open-label extension trial. An interim analysis of this trial evaluated the long-term safety and efficacy of Adbry among adolescents from ECZTRA 6 who moved into ECZTEND. The results of the analysis showed that the long-term safety profile of Adbry for up to three years in the adolescent population (n=127) was consistent with that of the ECZTEND adult population, with no new safety issues identified. Additionally, approximately eight out of 10 patients had at least a 75% improvement in the extent and severity of AD (EASI-75) at two years of treatment with Adtralza (84.4% AO (n=109), 78.7% mNRI (n=127), 78.7% LOCF (n=127). The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The use of Adbry in adolescent patients aged 12-17 is currently under clinical investigation and the safety and efficacy have not been fully evaluated by the U.S. FDA.
Related news and insights
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.
Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at risk of recurrence.
Iovance Biotherapeutics, Inc. announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting.